International Clinical Psychopharmacology最新文献_第8页

Immunomodulatory options for neurodevelopmental spectrum conditions: are we there yet? 神经发育谱系疾病的免疫调节方案：我们是否已经准备就绪？

IF 2.6 3区医学

International Clinical Psychopharmacology Pub Date : 2024-07-01 Epub Date: 2024-01-22 DOI: 10.1097/YIC.0000000000000531

Martina Arenella

{"title":"Immunomodulatory options for neurodevelopmental spectrum conditions: are we there yet?","authors":"Martina Arenella","doi":"10.1097/YIC.0000000000000531","DOIUrl":"10.1097/YIC.0000000000000531","url":null,"abstract":"About 3-7% of the worldwide population is diagnosed with a neurodevelopmental condition, including autism and attention-deficit hyperactivity disorder. Nonetheless, the aetiology of these conditions is unclear and support options are limited or not effective for all those diagnosed. Cumulating evidence, however, supports a role of the immune system in neurodevelopment, and immune dysregulations have been implicated in neurodevelopmental atypicalities. This knowledge offers tremendous opportunities, especially the possibility to adopt immunomodulatory compounds, which are already available and safe to use, for the management of neurodevelopmental difficulties. This perspective discusses the potential of immune-based interventions in neurodevelopmental care. Here, the application of existing immunomodulatory compounds to symptom management is justified by findings of immune dysregulations across neurodevelopmental conditions and preliminary, encouraging immune-based clinical trials. Still, key considerations are presented, specifically the necessity of immune biomarkers to ensure the right support option for the right (subgroup of) individuals within the neurodevelopmental spectrum.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"220-222"},"PeriodicalIF":2.6,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139541948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy and safety of agomelatine versus SSRIs/SNRIs for post-stroke depression: a systematic review and meta-analysis of randomized controlled trials. 阿戈美拉汀与SSRIs/SNRIs治疗脑卒中后抑郁症的疗效和安全性：随机对照试验的系统综述和荟萃分析。

IF 2.1 3区医学

International Clinical Psychopharmacology Pub Date : 2024-05-01 Epub Date: 2024-03-25 DOI: 10.1097/YIC.0000000000000509

Yicong Chen, Jianle Li, Mengshi Liao, Yinxin He, Chao Dang, Jian Yu, Shihui Xing, Jinsheng Zeng

{"title":"Efficacy and safety of agomelatine versus SSRIs/SNRIs for post-stroke depression: a systematic review and meta-analysis of randomized controlled trials.","authors":"Yicong Chen, Jianle Li, Mengshi Liao, Yinxin He, Chao Dang, Jian Yu, Shihui Xing, Jinsheng Zeng","doi":"10.1097/YIC.0000000000000509","DOIUrl":"10.1097/YIC.0000000000000509","url":null,"abstract":"Agomelatine is effective in the treatment of depression, but its effect for post-stroke depression (PSD) remains unclear. This study was conducted to compare the efficacy and safety of agomelatine versus SSRIs/SNRIs in treating PSD. We systematically searched Embase, PubMed, Cochrane Library, WanFang Data, China National Knowledge Infrastructure, and Cqvip databases for double-blind randomized controlled studies comparing the efficacy and safety of agomelatine versus SSRIs/SNRIs for PSD until December 2022. The primary efficacy endpoint was the Hamilton Depression Rating Scale (HAMD) score, and the primary safety endpoint was the incidence of overall adverse reactions. Nine studies comprising 857 patients with PSD were included. After 6-12 weeks of treatment, the HAMD score ( P = 0.16) and the overall response rates ( P = 0.20) in the agomelatine group were comparable to that in the SSRIs/SNRIs group. Participants treated with agomelatine achieved higher Barthel Index scores compared with the SSRIs/SNRIs group ( P = 0.02). There was a significantly lower incidence of overall adverse reactions ( P = 0.008) and neurological adverse reactions ( P < 0.0001) in the agomelatine group. The efficacy of agomelatine for treating PSD is probably comparable to that of SSRIs/SNRIs, and it may improve stroke outcomes with better safety.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"163-173"},"PeriodicalIF":2.1,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41125290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The role of benzodiazepines in common conditions: a narrative review focusing on lormetazepam. 苯二氮卓类药物在常见疾病中的作用：以洛美西泮为重点的叙述性综述。

IF 2.1 3区医学

International Clinical Psychopharmacology Pub Date : 2024-05-01 Epub Date: 2024-02-13 DOI: 10.1097/YIC.0000000000000529

Stefano Pallanti

{"title":"The role of benzodiazepines in common conditions: a narrative review focusing on lormetazepam.","authors":"Stefano Pallanti","doi":"10.1097/YIC.0000000000000529","DOIUrl":"10.1097/YIC.0000000000000529","url":null,"abstract":"This review aimed to examine the place of benzodiazepines, specifically lormetazepam, in the treatment of insomnia, including during pregnancy or in patients with psychodermatoses. PubMed was searched for the term \"lormetazepam\" in association with MeSH terms encompassing anxiety, insomnia/sleep disorders, pregnancy/gestation, and psychodermatoses/skin disorders. English-language articles up to 31 July 2022 were identified. Ad hoc searches for relevant literature were performed at later stages of review development. Multiple randomized, placebo-controlled studies have demonstrated that lormetazepam dose-dependently increases total sleep time, decreases wakefulness over a dosing range of 0.5-2.0 mg, and improves subjective assessments of sleep quality. Lormetazepam is as effective as other benzodiazepines in improving sleep duration and quality, but is better tolerated than the long-acting agents with minimal next-day effects. Benzodiazepines can be used as short-term monotherapy at the lowest effective dose during the second or third trimesters of pregnancy; lormetazepam is also a reasonable choice due to its limited transplacental passage. Insomnia associated with skin disorders or pregnancy can be managed by effective symptom control (especially itching), sleep hygiene, treatment of anxiety/depression, and a short course of hypnotics.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"139-147"},"PeriodicalIF":2.1,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10965132/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139566251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The effects of psychological flexibility and resilience on psychopharmacological treatment response in patients with obsessive-compulsive disorder. 心理灵活性和复原力对强迫症患者精神药物治疗反应的影响。

IF 2.6 3区医学

International Clinical Psychopharmacology Pub Date : 2024-05-01 Epub Date: 2023-08-07 DOI: 10.1097/YIC.0000000000000499

Nisa Deveci, Mustafa Uğurlu, Görkem Karakaş Uğurlu, Esra Kabadayi Şahin, Ezgi Çisil Erdoğan, Ali Çayköylü

{"title":"The effects of psychological flexibility and resilience on psychopharmacological treatment response in patients with obsessive-compulsive disorder.","authors":"Nisa Deveci, Mustafa Uğurlu, Görkem Karakaş Uğurlu, Esra Kabadayi Şahin, Ezgi Çisil Erdoğan, Ali Çayköylü","doi":"10.1097/YIC.0000000000000499","DOIUrl":"10.1097/YIC.0000000000000499","url":null,"abstract":"Obsessive-compulsive disorder (OCD) is a challenging psychiatric condition to treat. Previous research has explored various aspects of treatment response, but limited attention has been given to the significance of psychological flexibility and resilience. This study aimed to investigate the correlation between psychological flexibility, resilience, and different dimensions of OCD, as well as their role in treatment response specifically concerning OCD symptom sub-dimensions. The study involved 50 OCD patients and 42 healthy individuals as controls. Participants completed the Dimensional Obsessive-Compulsive Scale (DOCS), Acceptance and Action Questionnaire (AAQ-2), and Resilience Scale for Adults (RS). Initial scale scores were compared to post-treatment scores obtained after a 3-month follow-up using pharmacotherapy. The patient group exhibited significantly higher AAQ-2 scores and lower RS scores compared to the control group. During the post-treatment follow-up, a reduction in DOCS and AAQ-2 scores was observed, along with an increase in RS scores. The impact of differences in AAQ-2 and RS scores on the change in DOCS total scores was analyzed using mixed model linear regression analysis. The results showed a statistically significant effect of changes in AAQ-2 and RS sub-dimension scores on the change in DOCS total scores. The findings highlight the importance of flexibility and resilience in influencing treatment response among patients with OCD. When conventional pharmacotherapy and psychotherapy approaches prove insufficient, interventions focused on enhancing flexibility and resilience may contribute to improved treatment outcomes.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"181-186"},"PeriodicalIF":2.6,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9954146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment of high dose of intravenous midazolam abuse: a case report. 大剂量咪达唑仑静脉注射滥用的治疗：病例报告。

IF 2.6 3区医学

International Clinical Psychopharmacology Pub Date : 2024-05-01 Epub Date: 2023-08-09 DOI: 10.1097/YIC.0000000000000486

Yeganeh Ramazani, Ahmad Nemati, Mohammad Moshiri, Mahdi Talebi, Mohammad Dadkhah, Leila Etemad

{"title":"Treatment of high dose of intravenous midazolam abuse: a case report.","authors":"Yeganeh Ramazani, Ahmad Nemati, Mohammad Moshiri, Mahdi Talebi, Mohammad Dadkhah, Leila Etemad","doi":"10.1097/YIC.0000000000000486","DOIUrl":"10.1097/YIC.0000000000000486","url":null,"abstract":"This study reports a rare case of high-dose midazolam abuse and Munchausen Syndrome. A 48-year-old female physician was referred by a psychiatrist to the Toxicology Department of Imam Reza Hospital for abstaining from 300 mg/day of parenteral midazolam. She had mimicked the symptoms of Crohn's disease; therefore, she had undergone 15 colonoscopies and 40 times MRI or CT scan, all of which were normal. Six months earlier, she had switched oral methadone to 30 mg/day of intravenous midazolam. She also had several skin lesions on injection sites that she considered pyoderma gangrenosum. When the total daily dose of intravenous midazolam was switched to oral bioequivalence of clonazepam, she could not tolerate withdrawal (Clinical Institute Withdrawal Assessment Scale-Benzodiazepines = 68). Therefore, she received midazolam again as a continuous intravenous infusion. Within 7 days, the whole dose was replaced by the bioequivalence oral dose of clonazepam. She was also treated with carbamazepine and cognitive behavior therapy. Afterward, she was transferred to the psychiatric ward for further psychiatric treatment. Dependency on a high dose of midazolam could be treated by tapering off the long-acting benzodiazepine.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"206-210"},"PeriodicalIF":2.6,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10332319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Elevated liver transaminases among patients with psychiatric disorders. 精神疾病患者肝转氨酶升高。

IF 2.6 3区医学

International Clinical Psychopharmacology Pub Date : 2024-05-01 Epub Date: 2024-03-25 DOI: 10.1097/YIC.0000000000000514

Eman Ali, Mona Ahmed Abdel Maksoud, Shaymaa M Arafa, Doaa Ibrahim, Ahmed El-Sayed Hassan, Omnia Awwad, Ahmed M Elbeltagy, Essam Elmahdi, Reham Elgarhi, Ahmed Embaby

{"title":"Elevated liver transaminases among patients with psychiatric disorders.","authors":"Eman Ali, Mona Ahmed Abdel Maksoud, Shaymaa M Arafa, Doaa Ibrahim, Ahmed El-Sayed Hassan, Omnia Awwad, Ahmed M Elbeltagy, Essam Elmahdi, Reham Elgarhi, Ahmed Embaby","doi":"10.1097/YIC.0000000000000514","DOIUrl":"10.1097/YIC.0000000000000514","url":null,"abstract":"Hepatocyte injury is assessed by serum aspartate transaminase and alanine transaminase estimation. In psychiatric populations, antipsychotic drugs (AD) are culprit in hepatic dysfunction. To assess transaminitis among psychiatric patients treated by AD. This cross-sectional study was conducted in Zagazig University Hospitals in Egypt, from December 2022 to February 2023. A total of 135 adult patients aged ≥ 18 years, were diagnosed with psychiatric disorders after exclusion of patients receiving any hepatotoxic drugs, viral hepatitis, having chronic liver or kidney diseases, diabetes mellitus, mental retardation, and pregnant females. Among the 135 patients, 104 (77.0%) were males. Their age was 32 ± 9, The most popular used class of AD was atypical AD 84 (62.2%). The overall incidence of transaminitis among patients receiving AD was 23/135 (17.04%) of patients; 13 (56.5%) were on atypical AD compared to 10 (43.5%) patients receiving combined AD, without any statistically significant difference. The use of AD in patients with psychiatric disorders is potentially safe with minimal transaminitis (<one-fold elevation). However, baseline and regular monitoring of serum aminotransferase is recommended during treatment.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"195-200"},"PeriodicalIF":2.6,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41138180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparative efficacy of various pharmacologic treatments for alcohol withdrawal syndrome: a systematic review and network meta-analysis. 酒精戒断综合征各种药物治疗的疗效比较：系统综述和网络荟萃分析。

IF 2.1 3区医学

International Clinical Psychopharmacology Pub Date : 2024-05-01 Epub Date: 2023-12-27 DOI: 10.1097/YIC.0000000000000526

Li Qu, Xue-Ping Ma, Alimujiang Simayi, Xiao-Li Wang, Gui-Ping Xu

{"title":"Comparative efficacy of various pharmacologic treatments for alcohol withdrawal syndrome: a systematic review and network meta-analysis.","authors":"Li Qu, Xue-Ping Ma, Alimujiang Simayi, Xiao-Li Wang, Gui-Ping Xu","doi":"10.1097/YIC.0000000000000526","DOIUrl":"10.1097/YIC.0000000000000526","url":null,"abstract":"This study was to compare multiple classes of medications and medication combinations to find alternatives or additives for patients not applicable to benzodiazepines (BZDs). We performed a network meta-analysis to assess the comparative effect of 11 pharmacologic treatments in patients with alcohol withdrawal syndrome. Forty-one studies were included, comprising a total sample size of 4187 participants. The pooled results from the randomized controlled trials showed that there was no significant difference in the Clinical Institute Withdrawal Assessment-Alcohol, revised (CIWA-Ar) reduction with other medications or medication combinations compared to BZDs. Compared to BZDs, the mean difference in ICU length of stay of anticonvulsants + BZDs was -1.71 days (95% CI = -2.82, -0.59). Efficacy rankings from cohort studies showed that anticonvulsant + BZDs were superior to other treatments in reducing CIWA-Ar scores and reducing the length of stay in the ICU. Synthesis results from randomized controlled trials indicate that there are currently no data suggesting that other medications or medication combinations can fully replace BZDs. However, synthetic results from observational studies have shown that BZDs are effective in the context of adjuvant anticonvulsant therapy, particularly with early use of gabapentin in combination with BZDs in the treatment of alcohol withdrawal syndrome, which represents a promising treatment option.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"148-162"},"PeriodicalIF":2.1,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139086731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prevalence of obsessive-compulsive symptoms and their psychosocial correlates among medical students during COVID-19 pandemic. 在 COVID-19 大流行期间，医科学生中强迫症状的流行率及其社会心理相关性。

IF 2.6 3区医学

International Clinical Psychopharmacology Pub Date : 2024-05-01 Epub Date: 2023-08-09 DOI: 10.1097/YIC.0000000000000476

Mahsa Nahidi, Zahra Mirza Hoseinzadeh Moghaddam, Hamed Tabesh, Lahya Afshari Saleh, Farahnaz Rohani, Sheikh Shoib

{"title":"Prevalence of obsessive-compulsive symptoms and their psychosocial correlates among medical students during COVID-19 pandemic.","authors":"Mahsa Nahidi, Zahra Mirza Hoseinzadeh Moghaddam, Hamed Tabesh, Lahya Afshari Saleh, Farahnaz Rohani, Sheikh Shoib","doi":"10.1097/YIC.0000000000000476","DOIUrl":"10.1097/YIC.0000000000000476","url":null,"abstract":"This study aimed to assess the prevalence of obsessive-compulsive symptoms (OCS) among medical students during COVID-19 pandemic and to evaluate their association with related sociodemographic features and other psychological symptoms. In this cross-sectional study, students from Mashhad University of Medical Sciences with no major exam in the preceding or following month were surveyed during April to August 2021 through stratified available sampling. Data were collected by a structured online questionnaire distributed through social media platforms. OCS were assessed using Obsessive-Compulsive Inventory-Revised (OCI-R) and COVID-related stress was evaluated using COVID Stress Scale (CSS). Overall, 347 students with a mean age of 22.67 ± 2.56 years were included in this study, of whom 30.3% had probable obsessive-compulsive disorder (OCD; OCI-R score ≥21). Mean CSS scores in students with and without probable OCD were 38.64 ± 19.82 and 26.72 ± 16.63, respectively ( P < 0.005). Total CSS score was significantly correlated with OCI-R score ( r = 0.38, P = 0.001). Around one-third of the medical students reported significant OCS during COVID-19 pandemic, which was associated with higher COVID-19-related stress. Further research provides insight into management of OCD and related disorders during the COVID-19 pandemic.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"174-180"},"PeriodicalIF":2.6,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9966654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Stroke, COVID-19, and other somatic aspects of psychiatric disorders treatments. 中风、COVID-19 和其他精神疾病的躯体治疗。

IF 2.6 3区医学

International Clinical Psychopharmacology Pub Date : 2024-05-01 Epub Date: 2024-03-25 DOI: 10.1097/YIC.0000000000000547

Alessandro Serretti

引用次数: 0

Lurasidone as add-on to fluoxetine in obsessive-compulsive disorder with comorbid restrictive anorexia: a case report. 鲁拉西酮作为氟西汀的附加治疗药物用于伴有限制性厌食症的强迫症：病例报告。

IF 2.6 3区医学

International Clinical Psychopharmacology Pub Date : 2024-05-01 Epub Date: 2023-08-09 DOI: 10.1097/YIC.0000000000000502

Laura Orsolini, Silvia Bellagamba, Umberto Volpe

{"title":"Lurasidone as add-on to fluoxetine in obsessive-compulsive disorder with comorbid restrictive anorexia: a case report.","authors":"Laura Orsolini, Silvia Bellagamba, Umberto Volpe","doi":"10.1097/YIC.0000000000000502","DOIUrl":"10.1097/YIC.0000000000000502","url":null,"abstract":"Obsessive-compulsive disorder (OCD) is a pervasive disabling disorder that may overlap with other psychiatric conditions, including anorexia nervosa. Recent guidelines recommend low doses of second-generation antipsychotics as add-on therapy to selective serotonin reuptake inhibitors (SSRIs) for those patients presenting OCD who display residual symptomatology. Here we report a clinical case of a 45-years-old woman affected by severe OCD in comorbidity with anorexia nervosa, restrictive type (AN-r), treated with fluoxetine (titrated up to 40 mg/day) in augmentation with low doses of lurasidone (37 mg/day). At baseline and during a 6 months-follow-up we administered Clinical Global Impression-Severity, Symptom Checklist-90 items, Y-BOCS-II (Yale-Brown Obsessive Compulsive Scale) and EDI-3 (Eating Disorder Inventory). After 1 month of augmentation treatment, a clinically significant response was observed on obsessive symptoms at Y-BOCS-II (≥35% Y-BOCS reduction) and eating symptomatology at EDI-3. Full remission was reported after 3 months (Y-BOCS scoring ≤14) ( P < 0.01). Further longitudinal and real-world effectiveness studies should be implemented to confirm these novel results, to investigate the potential of lurasidone as add-on strategy to SSRI in poor responder OCD patients, including treatment-resistant-OCD (tr-OCD), as well as in improving eating disorder symptomatology, whereas there is comorbidity with AN-r.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"211-214"},"PeriodicalIF":2.6,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10965133/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9966656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0